CVS Health Corporation (NYSE:CVS) Getting Somewhat Favorable News Coverage, Accern Reports
Media coverage about CVS Health Corporation (NYSE:CVS) has been trending somewhat positive recently, Accern reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CVS Health Corporation earned a coverage optimism score of 0.10 on Accern’s scale. Accern also gave news headlines about the pharmacy operator an impact score of 45.8982628498261 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Accern’s analysis:
- CVS Charges More for Generic Drugs Paid for With Insurance, Lawsuit Claims – NBCNews.com (nbcnews.com)
- CVS Hit With Generic Drug Pricing Class Action – Bloomberg BNA (bna.com)
- CVS Health Corp. – Value Analysis (NYSE:CVS) : August 9, 2017 (finance.yahoo.com)
- FY2017 Earnings Estimate for CVS Health Corporation (CVS) Issued By Oppenheimer Holdings (americanbankingnews.com)
- CVS Steps Further Onto Turf Of MDs — WSJ (foxbusiness.com)
CVS Health Corporation (NYSE CVS) traded up 1.09% during trading on Wednesday, reaching $79.43. The company had a trading volume of 4,902,205 shares. The firm has a market capitalization of $80.92 billion, a P/E ratio of 16.57 and a beta of 0.91. CVS Health Corporation has a one year low of $69.30 and a one year high of $98.44. The firm’s 50-day moving average price is $78.75 and its 200 day moving average price is $79.09. CVS Health Corporation also was the target of some unusual options trading on Monday. Traders bought 12,222 put options on the company. This is an increase of 254% compared to the average volume of 3,454 put options.
CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 EPS for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.02. The business had revenue of $45.69 billion for the quarter, compared to analysts’ expectations of $45.36 billion. CVS Health Corporation had a return on equity of 17.56% and a net margin of 2.86%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same period last year, the firm earned $1.32 earnings per share. Equities analysts forecast that CVS Health Corporation will post $5.87 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, August 3rd. Stockholders of record on Monday, July 24th were given a dividend of $0.50 per share. The ex-dividend date of this dividend was Thursday, July 20th. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.52%. CVS Health Corporation’s payout ratio is 41.67%.
A number of equities research analysts have commented on CVS shares. Leerink Swann set a $90.00 price objective on CVS Health Corporation and gave the company a “buy” rating in a research note on Tuesday, June 27th. Vetr cut CVS Health Corporation from a “strong-buy” rating to a “buy” rating and set a $88.97 price objective for the company. in a research note on Monday, June 12th. Tigress Financial started coverage on CVS Health Corporation in a research note on Thursday, April 27th. They issued a “buy” rating for the company. Guggenheim reissued a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. Finally, ValuEngine cut CVS Health Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Eight research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. CVS Health Corporation has an average rating of “Buy” and a consensus target price of $91.27.
In other news, EVP Helena Foulkes sold 20,333 shares of the firm’s stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $80.00, for a total transaction of $1,626,640.00. Following the completion of the transaction, the executive vice president now owns 59,301 shares in the company, valued at $4,744,080. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO David M. Denton sold 230,510 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $80.00, for a total value of $18,440,800.00. Following the transaction, the chief financial officer now owns 176,983 shares of the company’s stock, valued at approximately $14,158,640. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 271,175 shares of company stock valued at $21,632,597. Company insiders own 0.61% of the company’s stock.
CVS Health Corporation Company Profile
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.